Arslan Nuri, Miller Tom R, Dehdashti Farrokh, Battafarano Richard J, Siegel Barry A
Division of Nuclear Medicine, Mallinckrodt Institute of Radiology, St. Louis, MO 63110, USA.
Mol Imaging Biol. 2002 Jul;4(4):301-10. doi: 10.1016/s1536-1632(02)00011-2.
This work evaluates positron emission tomography (PET) with 2-deoxy-2-[18F]fluoro-D-glucose (FDG) in assessing response to therapy in patients with esophageal cancer.
Twenty-four patients underwent FDG-PET before (pre-Rx) and after (post-Rx) chemoradiation therapy; 20 then underwent esophagectomy. The response of the primary tumors was visually assessed, and tumor volume, peak tumor standardized uptake value (SUV(peak)), average SUV (SUV(ave)), and total lesion glycolysis were determined pre-treatment and post-treatment. Patients were divided into groups according to the absence (Group A) or presence (Group B) of residual tumor after neoadjuvant therapy.
Among the quantitative PET parameters for Group A (n = 6) and Group B (n = 18), only change in tumor volume identified complete responders. Quantitative PET indices were not different in patients with or without post-Rx esophagitis.
The change in tumor volume identifies patients with complete response to neoadjuvant therapy, and quantitative evaluation of the primary tumor cannot separate post-Rx inflammation from residual tumor.
本研究评估2-脱氧-2-[18F]氟-D-葡萄糖（FDG）正电子发射断层扫描（PET）在评估食管癌患者治疗反应中的应用。
24例患者在放化疗前（Rx前）和放化疗后（Rx后）接受了FDG-PET检查；其中20例随后接受了食管切除术。对原发肿瘤的反应进行视觉评估，并在治疗前和治疗后测定肿瘤体积、肿瘤标准化摄取值峰值（SUV(peak)）、平均SUV（SUV(ave)）和总病变糖酵解。根据新辅助治疗后有无残留肿瘤将患者分为两组（A组）或有残留肿瘤组（B组）。
在A组（n = 6）和B组（n = 18）的PET定量参数中，只有肿瘤体积的变化可识别完全缓解者。Rx后有或无食管炎患者的PET定量指标无差异。
肿瘤体积的变化可识别对新辅助治疗有完全反应的患者，对原发肿瘤的定量评估无法区分Rx后炎症与残留肿瘤。
